Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1030)	7/16/1998 4:55:00 PM
From: Rick Strange	Read Replies (1) \| Respond to of 1491

Ariella, Yes, Net usually means after everything is deducted but they go on to say that a portion would be used to recoup prior advances from BOL which makes me wonder about the 9%. Maybe if anyone talks to the company they can ask? I agree with your comments about the important numbers being Rx income which we won't start seeing until the third quarter. It is reassuring to start to see Lotemax and Alrex making it's way onto various formularies such as Washington State. Too often we focus upon detail people making office sales calls and forget about the 75% of the iceberg beneath the waves...getting on HMO and State repayment scheduals. I don't really have any comments about today's trading activity. Even at its 52 week high PARS was way undervalued so each drop in price represents an oportunity in my eyes just based upon the value of Lotemax and Alrex. LE-T and HU-211 are freebies.

To: Ariella who wrote (1030)	7/17/1998 12:47:00 AM
From: ROBERT M. SILVER	Respond to of 1491

Ariella, I am extremely encouraged by the cash flow of $900,000 from product in the pipeline. Here is my reasoning. I expected a net to pharmos of $250,000 or less from June sales in the pipeline. That this was exceeded was a great relief to see that the company overhead may be covered by their two products. More importantly if we assume that only 10% of the pharmacies that fill prescriptions received any supply then 90% of the pipeline remains unfilled. And if in each month 10% of the pipeline gets filled, it will take nine months to totally fill the pipeline. There is a good chance that the company can receive $! million a month for the rest of the year if the pipeline is filled in the manner I expect. Even if filled prescriptions total $100,000 in June and increase $100,000 each month, a modest number for sure by the 9th month the company will be getting sales equal to $1,000,000 per month as well. This company can logically turn a profit by the end of the year. My earlier forecast of $10.00 a share by December remains on target. Look for an up day tomorrow. Robert